Recent Finacing
Recent Raise
OncoSenX develops a late‑preclinical non‑viral LNP-delivered, selective non‑integrating DNA platform with engineered promoters and programmable logic gates to induce tumor‑specific cell death in solid tumors.
Focus Areas
Total Raised
Funding round
See the team members at OncoSenX.
